 Sana Biotechnology Inc NASDAQ: SANA has secured non-exclusive commercial rights to Beam Therapeutics Incs NASDAQ: BEAM CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. The license does not include any rights to base editing using Cas12b, which remains at Beam. 